FY2024 EPS Estimates for BioNTech Decreased by HC Wainwright

BioNTech SE (NASDAQ:BNTX - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for BioNTech in a research note issued on Tuesday, November 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($5.24) for the year, down from their prior estimate of ($3.92). HC Wainwright currently has a "Buy" rating and a $150.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($2.93) per share. HC Wainwright also issued estimates for BioNTech's Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.34% and a negative net margin of 15.16%. The company's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.73 EPS.

A number of other research analysts have also weighed in on the stock. Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. HSBC boosted their target price on BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft boosted their price objective on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, September 19th. Finally, TD Cowen decreased their target price on BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $134.69.

BioNTech Stock Performance

NASDAQ:BNTX traded up $1.24 during trading hours on Thursday, hitting $107.88. 578,546 shares of the company traded hands, compared to its average volume of 783,058. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The firm's 50-day simple moving average is $111.00 and its 200-day simple moving average is $96.31. BioNTech has a one year low of $76.53 and a one year high of $131.49.

Institutional Trading of BioNTech

A number of institutional investors have recently modified their holdings of the business. Candriam S.C.A. lifted its position in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after purchasing an additional 341,311 shares during the period. New York State Common Retirement Fund boosted its stake in BioNTech by 457.9% in the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock worth $25,900,000 after purchasing an additional 178,981 shares during the period. abrdn plc grew its holdings in BioNTech by 334.4% during the 3rd quarter. abrdn plc now owns 225,992 shares of the company's stock valued at $26,841,000 after buying an additional 173,969 shares in the last quarter. Finally, Lodestone Wealth Management LLC bought a new stake in shares of BioNTech during the third quarter valued at about $8,373,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.